Screening and eradication of
Anti-Bacterial Agents
/ administration & dosage
Antimicrobial Stewardship
Clinical Decision-Making
Cost-Benefit Analysis
Delphi Technique
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Bacterial
Early Detection of Cancer
Endoscopy, Gastrointestinal
Gastritis, Atrophic
/ microbiology
Gastroesophageal Reflux
Gastrointestinal Microbiome
Genetic Markers
Global Health
Helicobacter Infections
/ diagnosis
Helicobacter pylori
Humans
Metabolic Syndrome
Metaplasia
/ microbiology
Proton Pump Inhibitors
/ administration & dosage
Reinfection
Stomach Neoplasms
/ epidemiology
cancer prevention
gastric cancer
helicobacter pylori
helicobacter pylori - treatment
screening
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
28
06
2020
revised:
27
07
2020
accepted:
12
08
2020
pubmed:
3
10
2020
medline:
13
4
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
A global consensus meeting was held to review current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of 28 experts from 11 countries reviewed the evidence and modified the statements using the Delphi method, with consensus level predefined as ≥80% of agreement on each statement. The Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach was followed. Consensus was reached in 26 statements. At an individual level, eradication of Evidence supports the proposal that eradication therapy should be offered to all individuals infected with
Identifiants
pubmed: 33004546
pii: gutjnl-2020-322368
doi: 10.1136/gutjnl-2020-322368
doi:
Substances chimiques
Anti-Bacterial Agents
0
Genetic Markers
0
Proton Pump Inhibitors
0
Types de publication
Consensus Development Conference
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2093-2112Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: J-ML reports receiving lecture fees from Takeda Pharmaceuticals (Taiwan) and Abbott Laboratories. PM reports receiving advisory and lecture fees from Bayer, Mayoly Spindler and Nordmark. DYG is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel H. pylori therapies and has received research support for culture of Helicobacter pylori.